Tilray Medical today announced a regulatory milestone in Europe: INFARMED, Portugal’s National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical’s EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house.
The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.
With this authorization, Tilray Medical further differentiates its European production platform by embedding advanced testing capabilities directly within its EU-GMP infrastructure. The approval reinforces Cantanhede as a strategic center for cultivation, production, testing, and international supply, and comes as demand for trusted, pharmaceutical-grade medical cannabis continues to grow across regulated markets.
For Tilray Medical, bringing critical quality testing in-house creates an important operational advantage in the fast-evolving global medical cannabis market. By reducing reliance on third-party testing for flower lots, the Company can lower batch-release costs, shorten testing timelines, and move product more efficiently from harvest to release and sale. These capabilities strengthen Tilray Medical’s ability to manage supply across key international markets, including Germany, the United Kingdom, Poland, Italy, and other regulated medical cannabis markets, while supporting more reliable access for patients and commercial partners.
